Key Takeaways For Eli Lilly in the Pharmaceuticals industry, the PE, PB, and PS ratios are all high compared to its peers, indicating overvaluation. The low ROE, EBITDA, and gross profit suggest ...

Indianapolis-based pharmaceutical giant Eli Lilly and Company has purchased 30.9 acres of vacant land to the north and to the ...

Eli Lilly's (LLY.N), opens new tab high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the ...

Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...

Size means little in light of this company's prospects.

Eli Lilly's blockbuster weight loss drug Zepbound ... of Zepbound and Mounjaro during the period, according to the pharmaceutical giant. But those wholesalers tapped into some of that existing ...

Eli Lilly shares fell up to 10% after Q3 earnings missed Wall Street expectations, reporting $11.4 billion in revenue and ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Here is what Baron Funds said about Eli Lilly and Company (NYSE:LLY) in its second-quarter 2024 investor letter. “Shares of global pharmaceutical company Eli Lilly and Company (NYSE:LLY ...

In the effort to expand approaches to treating Alzheimer’s beyond targeting amyloid, some companies have sought to target ...